The amino acid N136 in HIV-1 reverse transcriptase qualifies as a target for new (NNRTI) drug design

Jan Balzarini; Johan Auwerx; Fátima Rodrı́guez-Barrios; Francesca Ceccherini‐Silberstein; Carlos Garcı́a-Aparicio; Sonsoles Velázquez; De Clercq Erik; Carlo Federico Perno; Marı́a-José Camarasa; Federico Gago

Related publications

Article1991

The TIBO-site on HIV-1 reverse transcriptase represents a new target for anti-HIV chemotherapy

Rudi Pauwels, Zeger Debyser, Koen Andries, Mitsuo Baba, Dominique Schols, Michael J. Kukla, Jan Desmyter, Paul A. J. Janssen, De Clercq Erik

Article1993

HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity against HIV-1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase

Jan Balzarini, Anna Karlsson, María‐Jesús Pérez‐Pérez, Lotta Vrang, Johan Walbers, Hong Zhang, Bo Öberg, Anne‐Mieke Vandamme, Marı́a-José Camarasa, De Clercq Erik

Article1991

New antiviral target on HIV-1 reverse transcriptase revealed by TIBO derivatives

Zeger Debyser, Rudi Pauwels, K Andries, Jan Desmyter, Michael J. Kukla, Paj Janssen, De Clercq Erik

Article2025

Structure-Based Drug Design Yields Diarylpyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Zhenzhen Zhou, Jie Guo, Xin Li, Jinyuan Wu, De Clercq Erik, Christophe Pannecouque, Peng Zhan, Dongwei Kang, Xinyong Liu

Article2012

Crystal Structures of HIV-1 Reverse Transcriptase with Picomolar Inhibitors Reveal Key Interactions for Drug Design

Kathleen M. Frey, Mariela Bollini, Andrea C. Mislak, José A. Cisneros, Ricardo Gallardo‐Macias, William L. Jorgensen, Karen S. Anderson

Journal of the American Chemical Society